Division of Thoracic Surgery, Department of Cardiac Thoracic and Vascular Surgery, University of Pisa, Pisa, Italy.
Eur J Cardiothorac Surg. 2012 Apr;41(4):e43-6; discussion e47. doi: 10.1093/ejcts/ezr322. Epub 2012 Feb 24.
The aim of this study was to report a single referral centre experience in robotic extended thymectomy for clinical early-stage thymomas, evaluating its safety, feasibility and efficacy, with special regard to oncological outcomes.
Between April 2002 and February 2011, we retrospectively selected all those patients who underwent robotic thymectomy for clinical early-stage thymomas. Operative time, morbidity, mortality, duration of hospitalization and overall and disease-free survival were analysed.
There were 14 patients (8 males, 6 females) with a mean age of 65.2 years (range 23-81). One patient suffered from myasthenia gravis. The WHO classifications were: A in two cases, AB in four cases, B1 in three cases, B2 in two cases and B3 in three cases. The Masaoka stages were: I in seven cases, IIA in four cases, IIB in two cases and III in one case. The mean operative time was 139 min. No intra-operative complication or death occurred. Conversion to open surgery was required in two cases. Minor complications occurred in two patients (14.2%) due to pleural effusion. The mean hospitalization was 4.0 days. Five patients underwent adjuvant radiotherapy. All patients were alive with no disease recurrence, with a median follow-up of 14.5 months (range 1-98).
Robotic thymectomy is a safe and feasible technique, with a short operative time and low morbidity. Even on a small series with short follow-up, robotic extended thymectomy for thymoma appeared to be an effective treatment for early-stage thymomas.
本研究旨在报告单一转诊中心在机器人辅助扩大胸腺切除术治疗临床早期胸腺瘤方面的经验，评估其安全性、可行性和疗效，特别关注肿瘤学结果。
2002 年 4 月至 2011 年 2 月，我们回顾性选择了所有接受机器人胸腺切除术治疗临床早期胸腺瘤的患者。分析了手术时间、发病率、死亡率、住院时间以及总生存率和无病生存率。
共有 14 例患者（8 例男性，6 例女性），平均年龄为 65.2 岁（范围 23-81 岁）。1 例患者患有重症肌无力。世界卫生组织分类为：A型 2 例，AB 型 4 例，B1 型 3 例，B2 型 2 例，B3 型 3 例。Masaoka 分期为：Ⅰ期 7 例，ⅡA 期 4 例，ⅡB 期 2 例，Ⅲ期 1 例。平均手术时间为 139 分钟。无术中并发症或死亡发生。有 2 例患者转为开放手术。2 例患者（14.2%）因胸腔积液出现轻微并发症。平均住院时间为 4.0 天。5 例患者接受了辅助放疗。所有患者均存活，无疾病复发，中位随访时间为 14.5 个月（范围 1-98 个月）。
机器人胸腺切除术是一种安全可行的技术，具有手术时间短、发病率低的特点。即使在随访时间较短的小系列中，机器人辅助扩大胸腺切除术治疗胸腺瘤似乎也是治疗早期胸腺瘤的有效方法。
